Literature DB >> 21679247

Radiofrequency ablation versus surgical resection as primary treatment of hepatocellular carcinoma meeting the Milan criteria: a systematic review.

Yun Ku Cho1, Hyunchul Rhim, Sangik Noh.   

Abstract

BACKGROUND AND AIM: Surgery is the standard treatment option for hepatocellular carcinoma (HCC) meeting the Milan criteria, defined as single HCC ≤ 5 cm in maximum diameter or up to three nodules ≤ 3 cm. However, favorable survival outcomes have also been reported for these HCCs following radiofrequency ablation (RFA).
METHODS: We performed a systematic review to compare the results of hepatic resection and percutaneous RFA as a primary treatment option of HCC meeting the Milan criteria. Studies were identified by searching MEDLINE on PubMed, the Cochrane Library database and CANCERLIT using appropriate key words.
RESULTS: In all six identified observational studies, there were no statistically significant differences in overall survival rates between the two treatment modalities. The results of two randomized trials are controversial, while the power of these randomized trials is too limited to reach a reliable conclusion. In practice, the choice of treatment between surgery and RFA largely depends on the relationship between the local recurrence and perioperative mortality rates of HCC patients. Following RFA, local recurrence rates are low when a minimal safety margin ≥ 4-5 mm is achieved. A previous simulation study of overall survival for very early stage HCC, defined as an asymptomatic solitary small HCC ≤ 2 cm, showed that primary RFA with a 9% local recurrence rate is comparable to surgical resection with a 3% operative mortality rate.
CONCLUSION: Acquisition of a sufficient safety margin seems to be a critical factor before recommending wider application of RFA as primary treatment for HCCs that meet the Milan criteria.
© 2011 Journal of Gastroenterology and Hepatology Foundation and Blackwell Publishing Asia Pty Ltd.

Entities:  

Mesh:

Year:  2011        PMID: 21679247     DOI: 10.1111/j.1440-1746.2011.06812.x

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  31 in total

1.  Clinical experience with cone-beam CT navigation for tumor ablation.

Authors:  Nadine Abi-Jaoudeh; Aradhana M Venkatesan; William Van der Sterren; Alessandro Radaelli; Bart Carelsen; Bradford J Wood
Journal:  J Vasc Interv Radiol       Date:  2015-02       Impact factor: 3.464

2.  Level of hepatitis B surface antigen might serve as a new marker to predict hepatocellular carcinoma recurrence following curative resection in patients with low viral load.

Authors:  Hua-Bang Zhou; Qiao-Mei Li; Zheng-Rong Zhong; Jing-Yi Hu; Xiao-Lan Jiang; Hao Wang; Hui Wang; Bing Yang; He-Ping Hu
Journal:  Am J Cancer Res       Date:  2015-01-15       Impact factor: 6.166

Review 3.  Ablation therapy for hepatocellular carcinoma: past, present and future perspectives.

Authors:  David J Niemeyer; Kerri A Simo; David A Iannitti; Iain H McKillop
Journal:  Hepat Oncol       Date:  2013-12-20

Review 4.  Efficacy and safety of percutaneous radiofrequency ablation versus surgical resection for small hepatocellular carcinoma: a meta-analysis of 23 studies.

Authors:  Qian Feng; Yugang Chi; Yanqian Liu; Ling Zhang; Qi Liu
Journal:  J Cancer Res Clin Oncol       Date:  2014-06-03       Impact factor: 4.553

5.  Induction of rapid, reproducible hepatic ablations using next-generation, high frequency irreversible electroporation (H-FIRE) in vivo.

Authors:  Imran A Siddiqui; Eduardo L Latouche; Matthew R DeWitt; Jacob H Swet; Russell C Kirks; Erin H Baker; David A Iannitti; Dionisios Vrochides; Rafael V Davalos; Iain H McKillop
Journal:  HPB (Oxford)       Date:  2016-07-26       Impact factor: 3.647

6.  Safety margin of radiofrequency ablation for hepatocellular carcinoma: a prospective study using magnetic resonance imaging with superparamagnetic iron oxide.

Authors:  Kuniaki Fukuda; Kensaku Mori; Naoyuki Hasegawa; Katsuhiro Nasu; Kazunori Ishige; Yoshikazu Okamoto; Masanari Shiigai; Masato Abei; Manabu Minami; Ichinosuke Hyodo
Journal:  Jpn J Radiol       Date:  2019-05-17       Impact factor: 2.374

7.  Macrophages induce CD47 upregulation via IL-6 and correlate with poor survival in hepatocellular carcinoma patients.

Authors:  Jing Chen; Dan-Xue Zheng; Xing-Juan Yu; Hong-Wei Sun; Yi-Tuo Xu; Yao-Jun Zhang; Jing Xu
Journal:  Oncoimmunology       Date:  2019-08-15       Impact factor: 8.110

8.  A functional and protein-protein interaction analysis of neuroepithelial cell transforming gene 1 in hepatocellular carcinoma.

Authors:  Ke Ye; Shi Chang; Jindong Li; Xinying Li; Yuedu Zhou; Zhiming Wang
Journal:  Tumour Biol       Date:  2014-08-12

9.  Modeling and validation of microwave ablations with internal vaporization.

Authors:  Jason Chiang; Sohan Birla; Mariajose Bedoya; David Jones; Jeyam Subbiah; Christopher L Brace
Journal:  IEEE Trans Biomed Eng       Date:  2014-10-15       Impact factor: 4.538

10.  Sorafenib in combination with transarterial chemoembolization and radiofrequency ablation in the treatment for unresectable hepatocellular carcinoma.

Authors:  Yong Li; You-Bing Zheng; Wei Zhao; Bing Liu; Bao-Shan Hu; Xu He; Jian-Wen Huang; Li-Gong Lu
Journal:  Med Oncol       Date:  2013-09-19       Impact factor: 3.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.